多基因风险评分用于定义结肠镜检查发现并切除腺瘤后的个体化监测间隔
该研究基于德国人群的病例对照研究,纳入4696例结直肠癌病例和3709例对照,利用140个结直肠癌相关单核苷酸多态性构建多基因风险评分,结合结肠镜检查史和腺瘤特征计算结直肠癌绝对风险。结果显示,低风险腺瘤且高多基因风险评分者及高风险腺瘤者(无论多基因风险评分高低)的10年绝对风险可在3至5年内达到无息肉者10年后的水平。作者认为多基因风险评分可能有助于定义个体化监测间隔,但其风险变异是否足以指导临床风险分层尚需进一步探索。
要点
- 低风险腺瘤且高多基因风险评分者及高风险腺瘤者(无论评分高低)的绝对风险在3至5年内达到无息肉者10年水平。
- 50岁无息肉男女的10年结直肠癌绝对风险为0.2%。
- 多基因风险评分可能有助于定义个体化监测间隔,但风险变异是否足以指导临床风险分层尚需进一步探索。
核心结论
- 考虑由多基因风险评分确定的结直肠癌遗传易感性,可能有助于在筛查结肠镜检查发现并切除腺瘤后定义个体化、风险适配的监测间隔。
- 多基因风险评分带来的风险变异是否足以指导临床风险分层尚需进一步探索。
研究设计与样本
- 基于德国人群的病例对照研究。
- 纳入4696例结直肠癌病例和3709例对照,获取既往结肠镜检查详细信息及基于140个结直肠癌相关单核苷酸多态性的多基因风险评分。
- 根据对照中多基因风险评分的三分位数将参与者分为低、中、高遗传风险。
- 计算基于多基因风险评分及结肠镜检查史和发现的结直肠癌绝对风险。
主要发现
- 观察到结直肠癌风险随多基因风险评分出现较大变异,包括在结肠镜检查发现并切除腺瘤的个体中。
- 50岁无息肉男女的估计10年结直肠癌绝对风险为0.2%,对于这些人群仅推荐10年后重复筛查结肠镜检查。
- 低风险腺瘤且低多基因风险评分者的绝对风险估计与上述无息肉者相当。
- 低风险腺瘤且高多基因风险评分者及高风险腺瘤者(无论多基因风险评分高低)在3至5年内达到相同的绝对风险水平。
关键数值与推荐
- 多基因风险评分基于140个结直肠癌相关单核苷酸多态性。
- 根据对照中多基因风险评分的三分位数分为低、中、高遗传风险。
- 50岁无息肉男女的估计10年结直肠癌绝对风险为0.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多基因风险评分带来的风险变异是否足以指导临床风险分层尚需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Polygenic risk scores (PRSs) could help to define personalized colorectal cancer (CRC) screening strategies. The aim of this study was to evaluate whether a PRS, along with adenoma characteristics, could help to define more personalized and risk-adapted surveillance intervals. METHODS: In a population-based, case-control study from Germany, detailed information on previous colonoscopies and a PRS based on 140 CRC-related, single-nucleotide polymorphisms was obtained from 4696 CRC cases and 3709 controls. Participants were classified as having low, medium, or high genetic risk according to tertiles of PRSs among controls. We calculated the absolute risk of CRC based on the PRS and colonoscopy history and findings. RESULTS: We observed major variations of CRC risk according to the PRS, including among individuals with detection and removal of adenomas at colonoscopy. For instance, the estimated 10-year absolute risk of CRC for 50-year-old men and women with no polyps, for whom repeat screening colonoscopy is recommended after 10 years only, was 0.2%. Equivalent absolute risks were estimated for people with low-risk adenomas and low PRS. However, the same levels of absolute risk were reached within 3 to 5 years by those with low-risk adenomas and high PRS and with high-risk adenomas irrespective of the PRS. CONCLUSIONS: Consideration of genetic predisposition to CRC risk, as determined by a PRS, could help to define personalized, risk-adapted surveillance intervals after detection and removal of adenomas at screening colonoscopy. However, whether the risk variation is strong enough to direct clinical risk stratification needs to be explored further.
引用
- Guo F, Edelmann D, Cardoso R, et al. Polygenic Risk Score for Defining Personalized Surveillance Intervals After Adenoma Detection and Removal at Colonoscopy. Clin Gastroenterol Hepatol. 2022. PMID: 35331942. doi:10.1016/j.cgh.2022.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。